- Pharmaceutical Executive: August 2025
- Volume 45
- Issue 6
The CAR-T Climb
Spotlighting efforts in precision medicine development, particularly the potential growth of CAR-T therapies in underserved global markets.
A common theme across our
Of course, a leading approach under the precision medicine umbrella is the development of CAR-T therapies for cancer. Such products, as you know, have been a reality for several years, with multiple proven successes in the market. Today, the CAR-T field is generating significant buzz for its continued market penetration and appeal globally—and the promise of new and more effective targeting methods being studied in the clinic. In fact, recent projections by Nova One Advisor predict the global CAR-T cell therapy market will reach $127.53 billion by 2033.
That leads us to a special
I encourage you to explore the piece and Liter’s insights, which I think offer a unique lens—and a nice snapshot example—of the opportunities and challenges associated with CAR-T therapy expansion and access. The chance for biopharma players, globally, to build on those “tiny promises, embers of hope for solid tumors,” as Liter notes, for instance.
Thanks for reading.
Mike Hennessy Jr. is Chairman and CEO of MJH Life Sciences
Articles in this issue
2 months ago
2025 Emerging Pharma Leaders2 months ago
An RNA-Guided Path2 months ago
Acceleration and Ambition2 months ago
Driving Disruption in Delivery2 months ago
Building Promise from Precision2 months ago
Determined Problem-Solver2 months ago
How to Get Product Iteration Right in HealthcareNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.